Howard G. Welgus - 17 Jan 2023 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Role
Director
Signature
/s/ Scott Burrows, as Attorney-in-Fact for Howard G. Welgus
Issuer symbol
ARQT
Transactions as of
17 Jan 2023
Transactions value $
-$102,375
Form type
4
Filing time
18 Jan 2023, 19:18:25
Previous filing
17 Nov 2022
Next filing
21 Feb 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARQT Common Stock Options Exercise $14.3K +8.5K +5.13% $1.68 174K 17 Jan 2023 Direct F1
transaction ARQT Common Stock Sale -$117K -8.5K -4.88% $13.72 166K 17 Jan 2023 Direct F1
holding ARQT Common Stock 25K 17 Jan 2023 By Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARQT Stock Option (right to buy) Options Exercise $0 -8.5K -21.01% $0.00 32K 17 Jan 2023 Common Stock 8.5K $1.68 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
F2 The securities are held of record by The Welgus Living Trust, of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
F3 The option began vesting on March 13, 2019 and will vest monthly over a four year period, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.